Trust Point Inc. Buys New Position in Pfizer Inc. (NYSE:PFE)

Trust Point Inc. bought a new stake in Pfizer Inc. (NYSE:PFEFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 51,752 shares of the biopharmaceutical company’s stock, valued at approximately $1,490,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Front Street Capital Management Inc. raised its stake in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares in the last quarter. Infrastructure Capital Advisors LLC raised its stake in shares of Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 284 shares in the last quarter. Castleview Partners LLC raised its stake in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 287 shares in the last quarter. United Bank raised its stake in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Finally, Compton Capital Management Inc. RI raised its stake in shares of Pfizer by 0.5% during the first quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after acquiring an additional 300 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4 %

Shares of PFE stock traded down $0.11 during mid-day trading on Wednesday, reaching $27.44. 14,854,476 shares of the company’s stock traded hands, compared to its average volume of 42,932,930. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22. The company has a market cap of $155.38 billion, a P/E ratio of 76.11, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $27.41 and its 200-day moving average price is $29.25.

Pfizer (NYSE:PFEGet Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.14 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Truist Financial decreased their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Finally, Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.88.

Read Our Latest Stock Analysis on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.